LINQ® Procedure vs. Conventional Medical Management for Sacroiliac Dysfunction

Prospective, multi-center, open-label, randomized, clinical study. Subjects who meet the eligibility criteria and are enrolled will be randomized 2:1 to LINQ or CMM. After their 6 Month evaluations are complete, subjects in the Control Group can elect to stay in the CMM Arm or crossover to receive the LINQ procedure. Each subject will undergo a Screening Visit, Randomization, Baseline Procedure or CMM Initiation Visit, and Follow-Up Visits through 24 Months. The primary endpoint is evaluated at the 6 Month Follow Up Visit. Subjects that elect to crossover from the Control Group to the Treatment Group at the 6 Month Visit, will have Procedure and Follow-Up Visits through 18 Months post crossover procedure.